Voucher Bargain: US FDA Lowers Redemption Fee; NDA And BLA Review Costs Decrease
Additional fee will be less than traditional PDUFA application fee in FY 2019, meaning voucher redemptions will cost less than double a typical application review.
You may also be interested in...
Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.
Recruiting for “Cures”-funded positions resulted in two hires, then got an HHS review; onboarding time should be reduced significantly, but finding the money to pay the higher salaries remains a challenge under the new process.
Second consecutive year of record workload levels drive substantial increase in FDA's prescription drug user fee revenue target for fiscal year 2019.